[ibd-display-video id=449435 width=50 float=left autostart=true] The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they begin to launch a significant move.
Neogen has now climbed above a proper buy zone after clearing the 70.07 entry in a flat base.
The stock sports a 92 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 92% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company posted a 19% EPS gain for Q1. Sales growth increased 14%, up from 10% in the prior quarter. That marks one quarter of increasing revenue increases.
Neogen earns the No. 10 rank among its peers in the Medical-Products industry group. Abiomed ( ABMD ), Align Technology ( ALGN ) and Lemaitre Vascular ( LMAT ) are among the top 5 highly-rated stocks within the group.